Monoclonal antibody | |
---|---|
Type | ? |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Temelimab (also known as GNbAC1 [1] ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W. [2] [3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. [1] As of 2023, it is also being studied for cognitive impairment in long COVID. [4]